MOTS-c peptide injection: reconstitution and use protocol

Last updated 2026-07-24

What is a MOTS-c peptide injection, exactly?

MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome, in the region that overlaps the 12S rRNA gene. It's not a hormone your body secretes into the bloodstream in large amounts under normal conditions; it's a stress-response signal that mitochondria produce and that appears to move into the nucleus to change gene expression when a cell is under metabolic strain ^[1]. A "MOTS-c peptide injection" refers to subcutaneous administration of a synthesized version of this peptide, sold as a lyophilized (freeze-dried) powder that a person reconstitutes with a liquid diluent before drawing it into a syringe. That's the mechanical description. What it is NOT is an FDA-approved drug. There's no Drugs@FDA listing for MOTS-c ^[2], no approved indication, and no package insert with an established dose. Everything you read about injection protocols, including this article, is synthesizing research-grade pharmacology and compounding-pharmacy convention, not citing an approved label. If you want the deeper mechanistic background before you get into needles and vials, the MOTS-c overview is the place to start.

How do you reconstitute MOTS-c peptide?

Reconstitution just means adding sterile liquid back to the freeze-dried peptide powder so it can be drawn into a syringe. The two things that matter are sterility and getting the concentration right; get either wrong and you either risk contamination or you have no idea how much peptide is actually in your syringe. The common approach used across peptide compounding is: swab the vial tops with an alcohol wipe, draw bacteriostatic water (water with 0.9% benzyl alcohol as a preservative) into a syringe, and inject it slowly down the side of the vial wall, not directly onto the powder. Direct high-pressure streams onto lyophilized powder can denature the peptide structure. Swirl gently or let the vial sit; don't shake it hard. A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL, or 500 mcg per 0.1 mL mark on an insulin syringe. Reconstituted with 1 mL, you get 10 mg/mL, meaning smaller draw volumes for the same dose, which some people prefer for precision at low doses. There's no clinical trial establishing which dilution is "correct" for MOTS-c specifically; this is the same math used across the compounded peptide space generally. Once reconstituted, refrigerate the vial (not freeze) and most compounding guidance treats these peptides as stable for a few weeks refrigerated, though exact stability data specific to MOTS-c reconstituted solution isn't published in a way we can cite with confidence. If you see cloudiness, discoloration, or particulate matter, that vial is done. Throw it out.

How do you use a MOTS-c peptide injection pen or syringe?

Most MOTS-c products on the market ship as a vial plus a separate insulin syringe, not a pre-loaded pen. "MOTS-c peptide injection pen" is a phrase people search for, but true pen-injector delivery systems (like what's used for insulin or GLP-1 drugs) aren't standard for MOTS-c products from compounding sources as of now. What you'll typically use is a 29-31 gauge insulin syringe, 0.5 mL or 1 mL, with markings in units or mL. The injection itself is subcutaneous, meaning into the fat layer just under the skin, not into muscle. Common sites are the abdomen (two inches from the navel), the outer thigh, or the back of the upper arm if someone else is administering it. Rotate sites if you're injecting daily or near-daily; repeated injections in the same spot can cause local irritation or lipohypertrophy over time (a general injection-site principle, not something studied specifically for MOTS-c). Draw the dose, hold the syringe at roughly a 45 to 90 degree angle depending on how much subcutaneous fat is at the site, pinch a fold of skin, and inject steadily. There's no evidence-based rationale for injecting at a specific time relative to meals for MOTS-c the way there is for, say, insulin. Some protocols suggest morning dosing to align with circadian metabolic activity, but that's inference from exercise physiology research, not a finding from a MOTS-c human trial. For more on timing logic, see when to take MOTS-c peptide.

What dose of MOTS-c is actually used, and where does the number come from?

This is the honest, uncomfortable part. There is no FDA-approved dose because there is no FDA-approved product. Doses circulating in compounding and research-peptide communities (commonly cited ranges in the low single-digit milligrams, dosed a few times a week) are extrapolated from the animal studies, scaled by body weight, and refined by informal user reports, not derived from a published human dose-ranging trial. The foundational animal data used mouse models. The 2015 Cell Metabolism paper that first characterized MOTS-c's metabolic effects showed that in mice, it "promotes metabolic homeostasis and reduces obesity and insulin resistance," including in diet-induced and age-induced insulin resistance models ^[3]. That's a real, specific, citable finding. It is also a mouse study. Mouse-to-human dose conversion is a real pharmacology practice (typically using body surface area scaling), but nobody has published that conversion validated against actual human pharmacokinetic data for MOTS-c. For a fuller breakdown of the numbers people actually use and where the uncertainty sits, see the dedicated MOTS-c dosage page and the MOTS-c 10mg dosage calculator if you want to work through vial math. But go in knowing: any specific mg number you see quoted online is an estimate stacked on an estimate, not a clinical finding.

Is MOTS-c legal to buy and inject in the US?

MOTS-c sits in a gray zone that's worth understanding before you buy anything. It is not on the FDA's 503A Bulks List, the list of bulk drug substances that compounding pharmacies can legally use under Section 503A of the Food, Drug and Cosmetic Act [21 U.S.C. 353a] to make patient-specific compounded medications ^[4][5]. It's also not on the parallel 503B Bulks List for outsourcing facilities ^[6]. That matters practically. Substances not on either bulks list are not supposed to be compounded into human drug products by FDA-regulated pharmacies for prescribing to patients, no matter how many providers offer it. FDA's own bulk drug substance guidance page lays out the process by which a substance gets nominated and reviewed for the 503A list ^[5], and the current nominated list ^[2] is where you'd check status, but nomination isn't the same as approval. In practice, MOTS-c is mostly sold labeled "for research use only, not for human consumption," which is a legal fig leaf that a lot of buyers ignore. If a seller is marketing it with dosing instructions for human injection while using research-use-only language, that's an internal contradiction worth noticing. It doesn't mean the product is fake; it means the regulatory status hasn't caught up with the market. If you're deciding where to source it at all, the MOTS-c peptide buy guide covers what separates a provider-reviewed pathway from an anonymous research-chemical listing.

What does the human evidence for MOTS-c actually show, versus mouse and cell data?

This is the core problem with everything sold under the MOTS-c name: the interesting mechanism is real, and it's almost entirely un-tested in humans. Here's a rough map of what's been studied and in what model:

Every single one of those is a preclinical finding. A 2023 review in Frontiers in Endocrinology frames MOTS-c as "a promising mitochondrial-derived peptide for therapeutic exploitation" ^[1], which is an accurate summary: promising, not proven. A separate 2023 review calls it a peptide that "functionally prevents metabolic disorders," again based on the accumulated preclinical dataset ^[13]. The closest thing to human-relevant safety data isn't even MOTS-c specific. A 2026 Sports Medicine paper reviewing "Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance" ^[14] covers the peptide therapy landscape broadly, including unapproved compounds athletes use, and it's a useful frame for how thin the safety data is across this entire category, more than MOTS-c.

Is MOTS-c really "exercise in a pill"?

No, and that phrase should make you skeptical whenever you see it in marketing copy. What's true is narrower and more interesting: MOTS-c blood levels change in response to exercise in some human studies, and MOTS-c is proposed as part of the mitohormesis pathway, the idea that mild mitochondrial stress (like a hard workout) triggers adaptive signaling ^[15]. A 2022 review in Diabetes & Metabolism Journal specifically discusses "Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c)" ^[16], laying out the correlative link between exercise and this peptide's activity. Another 2021 review covers "Mitochondrial-derived peptides and exercise" more broadly ^[15]. These are legitimate scientific questions being actively studied. But correlation between exercise and endogenous MOTS-c levels in animal or limited human sampling is not the same claim as "injecting synthetic MOTS-c gives you the metabolic benefits of exercise." Nobody has run a trial testing whether injected MOTS-c produces exercise-equivalent outcomes in humans, on any endpoint: not VO2 max, not insulin sensitivity, not muscle mass. The Scientific Reports 2025 paper title itself, "MOTS-c mimics exercise to combat diabetic liver fibrosis," ^[11] is describing a mouse liver fibrosis model, using "mimics exercise" as a mechanistic descriptor for the pathway it activates (Keap1-Nrf2-Smad2/3), not a claim that the mouse got fitter. Read the actual methods before you let the title do the marketing for you.

What is MOTS-c being studied for beyond metabolism?

The metabolic story gets most of the attention, but the preclinical pipeline on MOTS-c has sprawled into some genuinely surprising directions, which is part of why researchers find it interesting even without human trials yet. Muscle and bone: a 2021 study found MOTS-c "reduces myostatin and muscle atrophy signaling" in a rodent model ^[17], and a 2024 paper found it attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration ^[18]. Separately, MOTS-c has a proposed role in bone metabolism regulation, per a 2023 Frontiers in Physiology review ^[19], and in cartilage protection via an Nrf2-dependent mechanism in a 2025 osteoarthritis model ^[20]. Organ injury and infection: a 2025 Redox Biology paper found MOTS-c attenuates lung ischemia-reperfusion injury via a MYH9-dependent mechanism in an animal model ^[21]. A 2024 Gut paper found a novel antiviral role during HBV infection tied to mitochondrial remodeling ^[22]. There's also work on lung injury from cardiopulmonary bypass ^[23], acute lung injury via ferroptosis suppression ^[24], pulmonary fibrosis ^[25], and allergic asthma airway barrier function ^[26], all preclinical. Cancer and cell repair: beyond the ovarian cancer paper ^[9], there's a 2024 Theranostics study on MOTS-c helping plasma membrane repair via TRIM72 translocation ^[27], and a 2026 Autophagy paper on lysosomal membrane permeability in soft tissue transplantation ^[28]. There's even a 2018 Rejuvenation Research paper worth flagging for balance: it reports mitochondrial-derived peptides can, in certain contexts, exacerbate senescence ^[29], a reminder that this biology isn't uniformly protective in every model. None of this is a human trial. All of it is a reason researchers keep publishing on MOTS-c. Those are different statements and worth holding separately.

What are the known or suspected side effects of MOTS-c injections?

Because there's no completed human clinical trial with published adverse event data, there is no adverse event table to cite the way you could for an approved drug. That absence of data is itself the honest answer, and it's a bigger deal than it sounds: it means nobody knows the real-world rate of injection site reactions, systemic effects, or long-term risks from repeated dosing in humans. What people report anecdotally in compounding and research-peptide communities includes injection site redness or itching (common to most subcutaneous peptide injections, not MOTS-c specific), and occasional reports of headache or fatigue. None of that is validated in a controlled study. For a fuller rundown of what's reported, what's plausible mechanistically, and what's simply unknown, see MOTS-c side effects. The broader 2026 Sports Medicine review on unapproved peptide therapies ^[14] is a useful gut-check here: it exists specifically because athletes and biohackers are using compounds like this ahead of the safety data, and the sports medicine and anti-doping community is trying to catch up on characterizing risk. That paper covers the category, not MOTS-c specifically in isolation, but the framing applies directly.

How should you store MOTS-c before and after reconstitution?

Before reconstitution, lyophilized MOTS-c powder is generally kept in a refrigerator (typically cited as 2-8°C) or frozen, protected from light, exactly the way most peptide products are stored prior to use. There's no MOTS-c-specific stability study published that we can point you to; storage guidance here follows general peptide-handling convention rather than a MOTS-c pharmacokinetics paper. After you add bacteriostatic water, the clock changes. Once reconstituted, refrigerate (don't freeze) and use within the timeframe printed on your specific product's guidance, commonly a few weeks in compounding-community practice. Keep the vial away from light, and don't let it sit at room temperature for extended stretches between doses. Visual check every time: clear solution, no cloudiness, no floating particles. If you're not sure the cold chain held during shipping (a summer package left on a porch, for example), don't inject it. That's not caution for caution's sake; peptide structure and any preservative system in the diluent can both degrade with heat exposure, and you have no lab on hand to verify potency.

Who should not consider MOTS-c, and where does the provider-reviewed route fit?

Given the total absence of human trial safety data, the most defensible stance for anyone with an existing endocrine condition, cancer history, pregnancy, or a complex medication regimen is: don't self-experiment with an unapproved research peptide without medical supervision. The cancer angle specifically deserves a pause, given that the same peptide shows tumor-suppressive activity in an ovarian cancer model in one 2024 study ^[9]; a molecule with cancer-pathway activity in preclinical models is not one to inject casually if you have any personal or strong family cancer history, until there's actual human safety data. If you're going to pursue this despite the evidence gaps, the meaningfully lower-risk path is a provider-reviewed route rather than an anonymous research-chemical vendor: a licensed prescriber who understands the compounding landscape, sources from a pharmacy that can speak to sterility testing and third-party purity verification, and who monitors you rather than leaving you to interpret vial labels alone. MOTS-c Co's editorial position isn't that this makes MOTS-c safe or effective; it's that it removes the added risk of contamination, mislabeled concentration, or a product that isn't what the listing claims. MOTS-c Co doesn't compound or manufacture anything itself; it reviews providers and points readers toward the pharmacy partners that fulfill those provider-reviewed orders. For the sourcing comparison itself, the MOTS-c peptide buy guide walks through what to look for.

Frequently asked questions

How do you reconstitute MOTS-c peptide at home?

Swab the vial top with alcohol, then slowly inject bacteriostatic water down the vial wall (not directly onto the powder) using a sterile syringe. A 10 mg vial with 2 mL of bacteriostatic water gives roughly 5 mg/mL. Swirl gently, don't shake. Refrigerate after reconstitution and discard if the solution turns cloudy or shows particles.

What water do you use to reconstitute MOTS-c?

Bacteriostatic water (0.9% benzyl alcohol) is the standard diluent used across compounded peptides, including MOTS-c, because the preservative allows multiple draws from one vial over several weeks. Sterile water without a preservative is used for single-dose situations only, since it doesn't inhibit bacterial growth once opened.

Is there a MOTS-c peptide injection pen?

Not commonly. Most MOTS-c products ship as a lyophilized vial plus a separate insulin syringe (typically 29-31 gauge), rather than a pre-loaded pen device like those used for insulin or GLP-1 drugs. Pen-style delivery isn't standard in the current compounded-peptide market for MOTS-c.

What dose of MOTS-c is typically used?

There's no FDA-approved or clinically established human dose. Doses discussed in compounding and research-peptide communities are extrapolated from mouse studies like the 2015 Cell Metabolism paper (PMID 25738459), not from a published human dose-ranging trial. Treat any specific mg number you see online as an estimate, not a clinical finding.

Is MOTS-c FDA approved?

No. There is no Drugs@FDA listing for MOTS-c, and it does not appear on the FDA's 503A or 503B Bulks Lists that govern which substances compounding pharmacies can legally use for human prescriptions. Products are typically sold labeled for research use only.

Does MOTS-c actually mimic the effects of exercise?

Not proven in humans. MOTS-c is studied as part of the mitohormesis pathway, where mitochondrial stress from exercise may trigger adaptive signaling, and blood levels shift with exercise in some studies. But no trial has tested whether injecting synthetic MOTS-c reproduces exercise's effects on fitness, insulin sensitivity, or muscle mass in people.

What does the research actually show MOTS-c does in animals?

In mice, MOTS-c has been shown to reduce obesity and insulin resistance and improve metabolic homeostasis (Cell Metabolism, 2015, PMID 25738459). Other rodent and cell studies show effects on muscle atrophy, bone metabolism, lung injury, and even antiviral activity against hepatitis B. All of this is preclinical, not human data.

How long does reconstituted MOTS-c last in the fridge?

Compounding-community convention suggests a few weeks refrigerated, though no MOTS-c-specific stability study has been published to confirm an exact shelf life. Keep it cold (not frozen), protect it from light, and discard the vial immediately if you see cloudiness or particulate matter.

Can MOTS-c injections cause side effects?

There's no published human clinical trial with adverse event data, so the honest answer is that the real-world side effect rate is unknown. Anecdotal reports mention injection site irritation, which is common to subcutaneous peptide injections generally. See the dedicated side effects page for more detail on what's reported versus proven.

Where in the body do you inject MOTS-c?

Subcutaneously, meaning into the fat layer just under the skin, typically in the abdomen, outer thigh, or back of the upper arm. This is the same injection technique used for insulin. Rotate sites with repeated dosing to reduce local skin irritation, a general subcutaneous-injection principle rather than a MOTS-c-specific finding.

Is it legal to buy MOTS-c in the United States?

MOTS-c occupies a regulatory gray zone. It's not FDA-approved and isn't on either bulk drug substance list that governs legal pharmacy compounding, so most sellers market it as research-use-only. Buying it isn't itself clearly illegal, but injecting a research-labeled product as a human drug sits outside the intended-use framework FDA regulations describe.

Should someone with a cancer history avoid MOTS-c?

Given that MOTS-c shows tumor-pathway activity in preclinical models, including a 2024 study on ovarian cancer suppression via the USP7-LARS1 pathway (PMID 39321430), anyone with a personal or strong family cancer history should treat this as a reason for added caution and medical consultation, not a green light in either direction, since human safety data doesn't exist.

Sources

1. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): MOTS-c is described as a promising mitochondrial-derived peptide for therapeutic exploitation, based on preclinical findings
2. PubMed, Cell Metabolism 2015 (PMID 25738459): In mice, MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
3. PubMed, Cell Metabolism 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate gene expression in response to metabolic stress
4. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the bulk drug substances legally permitted for 503A pharmacy compounding, which does not include MOTS-c
5. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the bulk drug substances permitted for 503B outsourcing facility compounding, which does not include MOTS-c
6. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Describes the nomination and review process for substances to be added to the 503A bulk drug substances list
7. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): Current status list of nominated bulk drug substances under FDA review for compounding eligibility
8. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes mellitus model
9. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination in a preclinical model
10. PubMed, Experimental & Molecular Medicine 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes in a preclinical model
11. PubMed, Scientific Reports 2025 (PMID 40425777): MOTS-c mimics exercise-linked pathways to combat diabetic liver fibrosis in a mouse model via Keap1-Nrf2-Smad2/3
12. PubMed, iScience 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
13. PubMed, Metabolites 2023 (PMID 36677050): Review characterizing MOTS-c as functionally preventing metabolic disorders across preclinical studies
14. PubMed, Sports Medicine 2026 (PMID 41966639): Reviews safety and efficacy data gaps for approved and unapproved peptide therapies used for athletic performance
15. PubMed, Biochimica et Biophysica Acta 2021 (PMID 34520826): Reviews the relationship between mitochondrial-derived peptides, including MOTS-c, and exercise
16. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): Reviews exercise, mitohormesis, and MOTS-c signaling as a proposed adaptive stress pathway
17. PubMed, American Journal of Physiology 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling in a preclinical model
18. PubMed, American Journal of Physiology 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
19. PubMed, Frontiers in Physiology 2023 (PMID 37200834): Reviews MOTS-c's proposed role in the regulation of bone metabolism
20. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c attenuates pyroptosis and cartilage degradation in an osteoarthritis model via an Nrf2-dependent mechanism
21. PubMed, Redox Biology 2025 (PMID 40403491): MOTS-c attenuates lung ischemia-reperfusion injury via a MYH9-dependent mechanism in a preclinical model
22. PubMed, Gut 2024 (PMID 37788894): MOTS-c shows a novel antiviral role during hepatitis B infection tied to mitochondrial remodeling
23. PubMed, American Journal of Respiratory Cell and Molecular Biology 2025 (PMID 40035775): MOTS-c promotes glycolysis via AMPK-HIF-1a-PFKFB3 pathway to ameliorate cardiopulmonary bypass-induced lung injury in a preclinical model
24. PubMed, European Journal of Pharmacology 2023 (PMID 37290680): MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion in a preclinical model
25. PubMed, Mitochondrion 2023 (PMID 37307934): MOTS-c is discussed as a potential anti-pulmonary fibrosis factor derived from mitochondria
26. PubMed, International Immunopharmacology 2025 (PMID 40472776): MOTS-c attenuates airway barrier dysfunction in an allergic asthma model by inhibiting epithelial apoptosis
27. PubMed, Theranostics 2024 (PMID 39267782): MOTS-c participates in plasma membrane repair by facilitating TRIM72 translocation to the membrane
28. PubMed, Autophagy 2026 (PMID 42153537): MOTS-c ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation in a preclinical model
29. PubMed, Rejuvenation Research 2018 (PMID 30058454): Reports that mitochondrial-derived peptides can, in certain contexts, exacerbate cellular senescence